世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

肝胆道系疾患治療薬ウルソデオキシコール酸の世界市場成長2024-2030年


Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Growth 2024-2030

LPI(エルピーアイ情報)の最新調査によると、肝胆膵疾患向けウルソデオキシコール酸薬の世界市場規模は2023年に100万米ドルと評価されました。下流市場での需要の増加に伴い、肝胆道系疾患向けウルソデオキシコ... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年10月25日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
110 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(エルピーアイ情報)の最新調査によると、肝胆膵疾患向けウルソデオキシコール酸薬の世界市場規模は2023年に100万米ドルと評価されました。下流市場での需要の増加に伴い、肝胆道系疾患向けウルソデオキシコール酸医薬品の市場規模は、レビュー期間中の年平均成長率(CAGR)%で2030年までに100万米ドルに再調整されると予測されています。
この調査レポートは、世界の肝胆道疾患向けウルソデオキシコール酸薬市場の成長可能性を明らかにしています。肝胆道系疾患用ウルソデオキシコール酸薬は、今後の市場でも安定した成長が見込まれる。しかし、肝胆膵用ウルソデオキシコール酸製剤の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要である。市場プレーヤーは、肝胆道系疾患用ウルソデオキシコール酸市場がもたらす大きなチャンスを活かすために、研究開発に投資し、戦略的パートナーシップを築き、進化する消費者の嗜好に合わせた製品を提供する必要がある。
ウルソデオキシコール酸は胆汁酸の一種で、原発性胆汁性肝硬変(PBC)の治療、胆嚢が機能していない患者における放射線透過性胆石の溶解、小児における嚢胞性線維症に伴う肝胆道系疾患の治療に使用される。
世界の医薬品市場は、2022年には1,475億ドルに達し、今後6年間のCAGRは5%で成長する。医薬品市場には、化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造部門の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。
主な特徴
肝胆道系疾患用ウルソデオキシコール酸薬市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、肝胆道系疾患向けウルソデオキシコール酸薬市場の現在の規模と成長の概要を提供します。過去のデータ、タイプ別(カプセル、錠剤など)の市場細分化、地域別の内訳などが含まれます。
市場促進要因と課題:肝胆膵疾患向けウルソデオキシコール酸製剤市場の成長を促進する要因(政府規制、環境問題、技術進歩、消費者嗜好の変化など)を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、高額な初期費用など、業界が直面する課題も浮き彫りにすることができます。
競合情勢:当調査レポートでは、肝胆膵疾患向けウルソデオキシコール酸薬市場内の競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれています。また、新興プレーヤーとその市場に与える潜在的な影響にもスポットを当てています。
技術開発:本調査レポートでは、肝胆道疾患用ウルソデオキシコール酸製剤業界における最新の技術開発について掘り下げることができます。これには、肝胆膵疾患用ウルソデオキシコール酸製剤技術の進歩、肝胆膵疾患用ウルソデオキシコール酸製剤の新規参入、肝胆膵疾患用ウルソデオキシコール酸製剤の新規投資、肝胆膵疾患用ウルソデオキシコール酸製剤の将来を形作るその他のイノベーションなどが含まれます。
川下企業の好み:本レポートは、肝胆膵疾患用ウルソデオキシコール酸市場における顧客の購買行動や採用動向を明らかにします。顧客の購買決定や肝胆道系疾患用ウルソデオキシコール酸製剤の嗜好に影響を与える要因も含まれています。
政府の政策とインセンティブこの調査レポートは、肝胆膵用ウルソデオキシコール酸市場に対する政府の政策とインセンティブの影響を分析しています。これには、規制の枠組み、補助金、税制優遇措置、肝胆膵疾患向けウルソデオキシコール酸製剤市場の促進を目的としたその他の措置の評価が含まれます。また、これらの政策が市場成長を促進する効果についても評価しています。
環境への影響と持続可能性当調査レポートでは、肝胆膵疾患向けウルソデオキシコール酸薬市場の環境への影響と持続可能性の側面を評価しています。
市場予測と将来展望:当調査レポートでは、実施した分析に基づいて、肝胆道系疾患用ウルソデオキシコール酸製剤産業の市場予測と展望を提供しています。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会:本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、肝胆道疾患用ウルソデオキシコール酸薬市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場セグメンテーション
肝胆道系疾患向けウルソデオキシコール酸薬市場は、タイプ別と用途別に分けられます。2019年から2030年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を数量と金額で提供します。
タイプ別セグメント
カプセル剤
錠剤
用途別セグメント
原発性胆汁性肝硬変(PBC)
胆石症
その他
また、本レポートでは地域別に市場を分割しています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ファルク・ファーマ
大雄製薬
テバ
ヒューマンウェル
田辺三菱製薬
ランネット
マイラン
ブルシェッティーニ
インパックス
上海製薬
グリンデクス
本レポートで扱う主な質問
肝胆道疾患治療薬ウルソデオキシコール酸の世界市場10年見通しは?
肝胆道系疾患用ウルソデオキシコール酸製剤の世界市場および地域別市場成長を促進する要因は何か?
市場別、地域別で最も急成長する技術は何か?
肝胆道疾患用ウルソデオキシコール酸製剤の市場機会は最終市場規模によってどのように異なるのか?
肝胆道疾患用ウルソデオキシコール酸製剤のタイプ別、用途別内訳は?


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country/Region, 2019, 2023 & 2030
2.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Type
2.2.1 Capsule
2.2.2 Tablet
2.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
2.3.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share by Type (2019-2024)
2.3.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue and Market Share by Type (2019-2024)
2.3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Type (2019-2024)
2.4 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Application
2.4.1 Primary Biliary Cirrhosis(PBC)
2.4.2 Gallstones
2.4.3 Others
2.5 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
2.5.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Market Share by Application (2019-2024)
2.5.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue and Market Share by Application (2019-2024)
2.5.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Application (2019-2024)
3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Company
3.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Breakdown Data by Company
3.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Company (2019-2024)
3.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share by Company (2019-2024)
3.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Company (2019-2024)
3.2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Company (2019-2024)
3.2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share by Company (2019-2024)
3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Company
3.4 Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Location Distribution
3.4.2 Players Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region
4.1 World Historic Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size by Geographic Region (2019-2024)
4.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size by Country/Region (2019-2024)
4.2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Country/Region (2019-2024)
4.2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Country/Region (2019-2024)
4.3 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth
4.4 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth
4.5 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth
4.6 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth
5 Americas
5.1 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country
5.1.1 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024)
5.1.2 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024)
5.2 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
5.3 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Region
6.1.1 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Region (2019-2024)
6.1.2 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Region (2019-2024)
6.2 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
6.3 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country
7.1.1 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024)
7.1.2 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024)
7.2 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
7.3 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country
8.1.1 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024)
8.1.2 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024)
8.2 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
8.3 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases
10.3 Manufacturing Process Analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases
10.4 Industry Chain Structure of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Distributors
11.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Customer
12 World Forecast Review for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region
12.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size Forecast by Region
12.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Region (2025-2030)
12.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Type
12.7 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Application
13 Key Players Analysis
13.1 Dr. Falk Pharma
13.1.1 Dr. Falk Pharma Company Information
13.1.2 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.1.3 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Dr. Falk Pharma Main Business Overview
13.1.5 Dr. Falk Pharma Latest Developments
13.2 Daewoong Pharmaceutical
13.2.1 Daewoong Pharmaceutical Company Information
13.2.2 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.2.3 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Daewoong Pharmaceutical Main Business Overview
13.2.5 Daewoong Pharmaceutical Latest Developments
13.3 Teva
13.3.1 Teva Company Information
13.3.2 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.3.3 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Teva Main Business Overview
13.3.5 Teva Latest Developments
13.4 Humanwell
13.4.1 Humanwell Company Information
13.4.2 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.4.3 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Humanwell Main Business Overview
13.4.5 Humanwell Latest Developments
13.5 Mitsubishi Tanabe Pharma
13.5.1 Mitsubishi Tanabe Pharma Company Information
13.5.2 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.5.3 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Mitsubishi Tanabe Pharma Main Business Overview
13.5.5 Mitsubishi Tanabe Pharma Latest Developments
13.6 Lannett
13.6.1 Lannett Company Information
13.6.2 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.6.3 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Lannett Main Business Overview
13.6.5 Lannett Latest Developments
13.7 Mylan
13.7.1 Mylan Company Information
13.7.2 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.7.3 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Mylan Main Business Overview
13.7.5 Mylan Latest Developments
13.8 Bruschettini
13.8.1 Bruschettini Company Information
13.8.2 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.8.3 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Bruschettini Main Business Overview
13.8.5 Bruschettini Latest Developments
13.9 Impax
13.9.1 Impax Company Information
13.9.2 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.9.3 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Impax Main Business Overview
13.9.5 Impax Latest Developments
13.10 Shanghai Pharma
13.10.1 Shanghai Pharma Company Information
13.10.2 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.10.3 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shanghai Pharma Main Business Overview
13.10.5 Shanghai Pharma Latest Developments
13.11 Grindeks
13.11.1 Grindeks Company Information
13.11.2 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.11.3 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Grindeks Main Business Overview
13.11.5 Grindeks Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market size was valued at US$ million in 2023. With growing demand in downstream market, the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market.
Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis (PBC), dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market. It may include historical data, market segmentation by Type (e.g., Capsule, Tablet), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases industry. This include advancements in Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases technology, Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases new entrants, Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases new investment, and other innovations that are shaping the future of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market. It includes factors influencing customer ' purchasing decisions, preferences for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market.
Market Segmentation:
Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Capsule
Tablet
Segmentation by application
Primary Biliary Cirrhosis(PBC)
Gallstones
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Humanwell
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market?
What factors are driving Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market opportunities vary by end market size?
How does Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases break out type, application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country/Region, 2019, 2023 & 2030
2.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Type
2.2.1 Capsule
2.2.2 Tablet
2.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
2.3.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share by Type (2019-2024)
2.3.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue and Market Share by Type (2019-2024)
2.3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Type (2019-2024)
2.4 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Application
2.4.1 Primary Biliary Cirrhosis(PBC)
2.4.2 Gallstones
2.4.3 Others
2.5 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
2.5.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Market Share by Application (2019-2024)
2.5.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue and Market Share by Application (2019-2024)
2.5.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Application (2019-2024)
3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Company
3.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Breakdown Data by Company
3.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Company (2019-2024)
3.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share by Company (2019-2024)
3.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Company (2019-2024)
3.2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Company (2019-2024)
3.2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share by Company (2019-2024)
3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Company
3.4 Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Location Distribution
3.4.2 Players Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region
4.1 World Historic Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size by Geographic Region (2019-2024)
4.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size by Country/Region (2019-2024)
4.2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Country/Region (2019-2024)
4.2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Country/Region (2019-2024)
4.3 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth
4.4 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth
4.5 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth
4.6 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth
5 Americas
5.1 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country
5.1.1 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024)
5.1.2 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024)
5.2 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
5.3 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Region
6.1.1 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Region (2019-2024)
6.1.2 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Region (2019-2024)
6.2 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
6.3 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country
7.1.1 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024)
7.1.2 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024)
7.2 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
7.3 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country
8.1.1 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024)
8.1.2 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024)
8.2 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type
8.3 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases
10.3 Manufacturing Process Analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases
10.4 Industry Chain Structure of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Distributors
11.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Customer
12 World Forecast Review for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region
12.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size Forecast by Region
12.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Region (2025-2030)
12.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Type
12.7 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Application
13 Key Players Analysis
13.1 Dr. Falk Pharma
13.1.1 Dr. Falk Pharma Company Information
13.1.2 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.1.3 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Dr. Falk Pharma Main Business Overview
13.1.5 Dr. Falk Pharma Latest Developments
13.2 Daewoong Pharmaceutical
13.2.1 Daewoong Pharmaceutical Company Information
13.2.2 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.2.3 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Daewoong Pharmaceutical Main Business Overview
13.2.5 Daewoong Pharmaceutical Latest Developments
13.3 Teva
13.3.1 Teva Company Information
13.3.2 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.3.3 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Teva Main Business Overview
13.3.5 Teva Latest Developments
13.4 Humanwell
13.4.1 Humanwell Company Information
13.4.2 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.4.3 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Humanwell Main Business Overview
13.4.5 Humanwell Latest Developments
13.5 Mitsubishi Tanabe Pharma
13.5.1 Mitsubishi Tanabe Pharma Company Information
13.5.2 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.5.3 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Mitsubishi Tanabe Pharma Main Business Overview
13.5.5 Mitsubishi Tanabe Pharma Latest Developments
13.6 Lannett
13.6.1 Lannett Company Information
13.6.2 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.6.3 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Lannett Main Business Overview
13.6.5 Lannett Latest Developments
13.7 Mylan
13.7.1 Mylan Company Information
13.7.2 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.7.3 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Mylan Main Business Overview
13.7.5 Mylan Latest Developments
13.8 Bruschettini
13.8.1 Bruschettini Company Information
13.8.2 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.8.3 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Bruschettini Main Business Overview
13.8.5 Bruschettini Latest Developments
13.9 Impax
13.9.1 Impax Company Information
13.9.2 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.9.3 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Impax Main Business Overview
13.9.5 Impax Latest Developments
13.10 Shanghai Pharma
13.10.1 Shanghai Pharma Company Information
13.10.2 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.10.3 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shanghai Pharma Main Business Overview
13.10.5 Shanghai Pharma Latest Developments
13.11 Grindeks
13.11.1 Grindeks Company Information
13.11.2 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications
13.11.3 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Grindeks Main Business Overview
13.11.5 Grindeks Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医薬)の最新刊レポート

本レポートと同じKEY WORD(ursodeoxycholic)の最新刊レポート


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/05 10:26

151.38 円

159.59 円

194.97 円

ページTOPに戻る